WO2023199230 - OCT GUIDED THERAPY
National phase entry:
Publication Number
WO/2023/199230
Publication Date
19.10.2023
International Application No.
PCT/IB2023/053711
International Filing Date
11.04.2023
Title **
[English]
OCT GUIDED THERAPY
[French]
THÉRAPIE GUIDÉE PAR OCT
Applicants **
NOTAL VISION LTD.
Inventors
PASCAL, Amit
NAHEN, Kester
BENYAMINI, Hanoch Gideon
RAFAELI, Omer
ALSTER, Yair
HAVILIO, Moshe
ALON, Yael
BERGMAN, Elad
LEVY, Shelly Joy
Priority Data
63/330,666
13.04.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2511 | |
| EPO | Filing, Examination, Granting | 13895 | |
| Japan | Filing, Examination, Granting | 2223 | |
| South Korea | Filing, Examination, Granting | 2252 | |
| USA | Filing, Examination, Granting | 4310 |
Total:
25,191
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Systems for managing treatment of a retinal disease, predicting progression of a retinal disease, and classifying a retinal disease employ remote based OCT imaging of a subject's retina. A system for managing treatment of a retinal disease includes a communication unit, at least one processor, and a tangible storage device. The communication unit is configured to receive optical coherence tomography (OCT) image data of a retina of a subject for each of a series of OCT imaging sessions of the retina. The tangible storage device stores non-transitory instructions that are executable by the at least one processor to cause the at least one processor to process the OCT image data of the retina to determine a series of measured retinal fluid extent values and generate a treatment recommendation for the subject via execution of a treatment algorithm using input based on the series of measured retinal fluid extent values.[French]
Des systèmes de gestion du traitement d'une maladie rétinienne, de prédiction de la progression d'une maladie rétinienne, et de classification d'une maladie rétinienne utilisent une imagerie OCT à distance de la rétine d'un patient. Un système de gestion du traitement d'une maladie rétinienne comprend une unité de communication, au moins un processeur et un dispositif de stockage tangible. L'unité de communication est conçue pour recevoir des données d'image de tomographie par cohérence optique (OCT) d'une rétine d'un patient pour chacune d'une série de sessions d'imagerie OCT de la rétine. Le dispositif de stockage tangible stocke des instructions non transitoires qui sont exécutables par le ou les processeurs pour amener le ou les processeurs à traiter les données d'image OCT de la rétine pour déterminer une série de valeurs d'étendue de fluide rétinien mesurées et générer une recommandation de traitement pour le patient par l'exécution d'un algorithme de traitement à l'aide d'une entrée sur la base de la série de valeurs d'étendue de fluide rétinien mesurées.